Tech

Activist investor Politan plans second fight at Masimo

Key Points
  • Politan Capital, run by veteran activist Quentin Koffey, said it would seek two further board seats at health-tech firm Masimo.
  • Masimo shares rose 4% on the news, which came after the company announced it would seek to spin off a consumer-focused unit.
  • Politan's fight at Masimo was one of the most contentious proxy fights of the past few years and resulted in Koffey gaining two of six seats on the company's board.

In this article

Masimo CEO Joe Kiani.
Scott Mlyn | CNBC

Health-tech company Masimo, best known for its successful patent litigation over the Apple Watch, is facing a proxy fight for the second time in two years — from the same activist investor who now sits on the company's six-person board.

Quentin Koffey's Politan Capital, a roughly 9% shareholder, announced it would nominate two directors to Masimo's board, just days after the company announced it would seek to spin off an embattled business unit.

Shares surged on the news during Monday morning trading, before closing up around 3%.

Masimo announced Friday that it would explore a spinoff of its audio unit, which it acquired in 2022 for $1 billion. The acquisition, which frustrated some investors and was seen as unrelated to Masimo's core health-tech focus, prompted Politan's first proxy fight at the company.

Now, Politan is seeking two further board seats to ensure that the company follows through on the spinoff, which Politan said was "rushed" to announcement after the activist told the company it would seek additional board seats last week.

A Masimo spokesperson disputed that sequence of events. "It is Politan that rushed the announcement of its candidates this morning to try to take credit for the positive market reaction to the separation announcement," the spokesperson said.

Politan's nominees are former Agilent executive Darlene Solomon and former Stryker Chief Financial Officer Bill Jellison. Solomon oversaw research and development at Agilent, while Jellison helped drive Stryker's merger and acquisition strategy.

If successful, the activist investor would control four of the company's six board seats.

Politan already won two board seats for Koffey and health-care executive Michelle Brennan in its previous proxy fight, which was closely followed by investors given the intensity of the fight and unusual tactics by management to stave off Koffey.

Koffey said he had been initially "optimistic" that Masimo's board would work with Politan.

"Unfortunately, our efforts were continually rebuffed, as Chairman & CEO Joe Kiani refused to give us basic information, denied us access to management, repeatedly held Board meetings excluding us, and refused to even consider allowing any review of capital allocation or strategy," Koffey said in a release.

In the previous proxy fight, Kiani showed no desire to settle a fight with the activist fund. Some of Masimo's maneuvers to try and stave off Politan, such as an unprecedented attempt to force activists to detail their other investments and their clients before seeking a board nomination, drew widespread scrutiny.

Politan said in its release that it hoped to avoid another proxy fight.

"Darlene and Bill are indisputably qualified to help the Company and adding them immediately would have the benefit of avoiding a costly and distracting contested election," Koffey said.

"Members of the Board, including Quentin Koffey, have been a key part of the discussions concerning the separation dating back to January, when Joe Kiani first proposed the idea following a listening tour with shareholders," a Masimo spokesperson said, noting that two-thirds of the company's board had joined within the past nine months.

The spokesperson added that the company had previously committed to reassessing the $1 billion Sound United strategy within three years.